Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
News Feb 06, 2011
Vermillion, Inc., a molecular diagnostics company, has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of breast cancer and to the measurement of the biomarkers by mass spectrometry.
"The notice of allowance for this breast cancer biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson of the Board of Directors of Vermillion.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019